Literature DB >> 22547692

Management of allergic bronchopulmonary aspergillosis: a review and update.

Mahboobeh Mahdavinia1, Leslie C Grammer.   

Abstract

Since the first description of allergic bronchopulmonary aspergillosis (ABPA) in the 1950s there have been numerous studies that have shed light on the characteristics and immunopathogenesis of this disease. The increased knowledge and awareness have resulted in earlier diagnosis and treatment of patients with this condition. This article aims to provide a summary and updates on ABPA by reviewing the results of recent studies on this disease with a focus on articles published within the last 5 years. A systematic search of PubMed/Medline with keywords of ABPA or allergic bronchopulmonary aspergillosis was performed. All selected articles were reviewed with a focus on findings of articles published from December 2006 to December 2011. The relevant findings are summarized in this paper.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547692     DOI: 10.1177/1753465812443094

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  12 in total

Review 1.  Allergic bronchopulmonary aspergillosis.

Authors:  Paul A Greenberger; Robert K Bush; Jeffrey G Demain; Amber Luong; Raymond G Slavin; Alan P Knutsen
Journal:  J Allergy Clin Immunol Pract       Date:  2014-11-06

2.  Unraveling the nanoscale surface properties of chitin synthase mutants of Aspergillus fumigatus and their biological implications.

Authors:  David Alsteens; Vishukumar Aimanianda; Pushpa Hegde; Stéphane Pire; Rémi Beau; Jagadeesh Bayry; Jean-Paul Latgé; Yves F Dufrêne
Journal:  Biophys J       Date:  2013-07-16       Impact factor: 4.033

Review 3.  Exposure and Health Effects of Fungi on Humans.

Authors:  Sachin N Baxi; Jay M Portnoy; Désirée Larenas-Linnemann; Wanda Phipatanakul
Journal:  J Allergy Clin Immunol Pract       Date:  2016-03-03

4.  Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring?

Authors:  Subramanian Natarajan; Poonam Subramanian
Journal:  Ann Thorac Med       Date:  2014-10       Impact factor: 2.219

5.  The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function.

Authors:  Jianmin Jin; Xiaofang Liu; Yongchang Sun
Journal:  Respir Res       Date:  2014-10-29

6.  Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.

Authors:  Rodrigo Abensur Athanazio; Luiz Vicente Ribeiro Ferreira da Silva Filho; Alberto Andrade Vergara; Antônio Fernando Ribeiro; Carlos Antônio Riedi; Elenara da Fonseca Andrade Procianoy; Fabíola Villac Adde; Francisco José Caldeira Reis; José Dirceu Ribeiro; Lídia Alice Torres; Marcelo Bicalho de Fuccio; Matias Epifanio; Mônica de Cássia Firmida; Neiva Damaceno; Norberto Ludwig-Neto; Paulo José Cauduro Maróstica; Samia Zahi Rached; Suzana Fonseca de Oliveira Melo
Journal:  J Bras Pneumol       Date:  2017 May-Jun       Impact factor: 2.624

Review 7.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Ibrahim Ahmed Janahi; Abdul Rehman; Amal Rashid Al-Naimi
Journal:  Ann Thorac Med       Date:  2017 Apr-Jun       Impact factor: 2.219

8.  Double-stranded RNA mycovirus infection of Aspergillus fumigatus is not dependent on the genetic make-up of the host.

Authors:  Jeannine M Refos; Alieke G Vonk; Kimberly Eadie; Jerome R Lo-Ten-Foe; Henri A Verbrugh; Anne D van Diepeningen; Wendy W J van de Sande
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

Review 9.  Allergic Bronchopulmonary Aspergillosis.

Authors:  Michael C Tracy; Caroline U A Okorie; Elizabeth A Foley; Richard B Moss
Journal:  J Fungi (Basel)       Date:  2016-06-06

10.  Case Report: Allergic Bronchopulmonary Aspergillosis Revealing Asthma.

Authors:  Houda Snen; Aicha Kallel; Hana Blibech; Sana Jemel; Nozha Ben Salah; Sonia Marouen; Nadia Mehiri; Slah Belhaj; Bechir Louzir; Kalthoum Kallel
Journal:  Front Immunol       Date:  2021-06-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.